DDrare: Database of Drug Development for Rare Diseases

274. 骨形成不全症
［臨床試験数：78，薬物数：87（DrugBank：19），標的遺伝子数：14，標的パスウェイ数：74］

Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACLASTA; AMG 162; AMG 785; ANTI-SCLEROSTIN MONOCLONAL ANTIBODY; Aclasta; Actonel 5mg Film Coated Tablets; Actonel Once a Week 35 mg film-coated tablets; Actonel/Optinate 5mg film-coated tablets; Alendronate; Alendronic acid; Anti-sclerostin monoclonal antibody; BOOST cells; BPS804; Bisphosphonates; Blood sample; Bone marrow transplant; Bonefos; Busulfan; Calcichew tablets; Calcium; Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida; Cyclophosphamide; Cyclosporin; Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas; Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088); DENOSUMAB; Denosumab; Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand; Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand; Denusomab; Disodium Pamidronate 15mg (15mg strength); Expanded human first trimester fetal liver-derived mesenchymal stem cells; Forsteo; Fresolimumab; GENOTROPIN*1TBF 5,3MG (16UI); H05AA02; High-dose vitamin D (2000 IU per day); Humatrope; Ibandronic acid; Ibandronic acid solution; Mesenchymal Stem Cells; Mesenchymal Stromal Cells; NERIXIA*INFUS IV CONC 2F 100MG; Optinate 5 mg filmcoated tablets; Other: Bone Marrow Cell Transplantation; Other: No active treatment; Other: saline; Pamidronate; Pamidronate (Aredia); Pamidronate sodium; Procedure: Mesenchymal Stem Cell Transplantation; Prolia; REF CRUZADA PEI Nº 12-088; RITUXIMAB; ROMOSOZUMAB; Radiation: Irradiation, Total Body; Risedronate; Risedronate Oral Tablet; Risedronate Sodium; Risedronate sodium; Risedronate sodium (Actonel); Risedronate sodium 2.5mg; Risedronate sodium 5mg; Risedronato sódico 2.5mg; Risedronato sódico 5mg; Risedronic acid; Rituximab; Romosozumab; Setrusumab; Somatropin; Standard-dose vitamin D (400IU per day); Teriparatide; Teriparatide (FORTEO); Teriparatide Pen Injector; VARI; Vitamin D; XGEVA; Xgeva; ZOL446; ZOLEDRONIC ACID; Zoledronic Acid; Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product; Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product.; Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product; Zoledronic acid; Zometa; Ácido risedrónico

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-005275-42-IT (EUCTR)	21/03/2005	23/01/2008	Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta	Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta	Osteogenesis Imperfecta MedDRA version: 6.1;Level: SOC;Classification code 10010331	Trade Name: GENOTROPIN1TBF 5,3MG (16UI) INN or Proposed INN: Somatropin Trade Name: NERIXIAINFUS IV CONC 2F 100MG INN or Proposed INN: VARI	AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA	NULL	Not Recruiting			Female: yes Male: yes			Italy
2	NCT00001305 (ClinicalTrials.gov)	November 5, 1991	3/11/1999	Growth Hormone Therapy in Osteogenesis Imperfecta	Studies of Growth Deficiency and Growth Hormone Treatment in Children With Osteogenesis Imperfecta Types III and IV	Osteogenesis Imperfecta	Drug: Humatrope	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	3 Years	16 Years	All	42	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2004-005275-42-IT
(EUCTR)

21/03/2005

23/01/2008

Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta

Osteogenesis Imperfecta
MedDRA version: 6.1;Level: SOC;Classification code 10010331

Trade Name: GENOTROPIN*1TBF 5,3MG (16UI)
INN or Proposed INN: Somatropin
Trade Name: NERIXIA*INFUS IV CONC 2F 100MG
INN or Proposed INN: VARI

AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA

NULL

Not Recruiting

Female: yes
Male: yes

Italy

NCT00001305
(ClinicalTrials.gov)

November 5, 1991

3/11/1999

Growth Hormone Therapy in Osteogenesis Imperfecta

Studies of Growth Deficiency and Growth Hormone Treatment in Children With Osteogenesis Imperfecta Types III and IV

Osteogenesis Imperfecta

Drug: Humatrope

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NULL

Completed

3 Years

16 Years

All

Phase 3

United States